Dangerous deception--Hiding the evidence of adverse drug effects
Article Abstract:
The New York Times reported on September 30, 2006 that the Food and Drug Administration had issued a warning that the antifibrinolytic drug aprotinin widely used to reduce perioperative bleeding in patients undergoing cardiac surgery, could cause renal failure, congestive heart failure, stroke, and death. In a study involving 4374 patients who underwent coronary revascularization it was found that patients who were given aprotinin had an incidence of postoperative renal failure requiring dialysis that was more than twice that among patients who received different agents.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Keeping science on top in drug evaluation
Article Abstract:
The article reviews the drug-approval procedures followed in the U.S. relevant to science and vested interests of pharmaceutical companies.
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Part 'D' for defective' - The Medicare drug benefit chaos. Zygote and "clonote" - the ethical use of embryonic stem cells
- Abstracts: On the preservation of health. Medical challenges of improving the quality of a longer life. Pandemic influenza preparedness and community resiliency
- Abstracts: Should nursing be an all degree profession? Making the most of a careers event. Making careers events work for you
- Abstracts: Working for free proposal sparks strong reaction from profession
- Abstracts: Acute epiglottitis. Auditing possible side-effects of atypical antipsychotics. Shifting pulmonary embolism management to primary care